Given the pivotal role of GM-CSF signaling in PAP, GM-CSF supplementation can be a valid therapeutic option for autoimmune PAP patients when enough GM-CSF is supplied to outperform the neutralizing antibodies [13]. This evidence concerns the gene CSF2 and pulmonary alveolar proteinosis.